✦ LIBER ✦

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

✍ Scribed by M. De Jonge; N. Steeghs; J. Verweij; J.W.R. Nortier; F. Eskens; J. Ouwerkerk; C.Van Noort; P. Carpinelli; R. Spinelli; F. Bologna; H. Gelderblom

Book ID: 118623655
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 82 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70032-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

343 POSTER Phase I dose escalation study

343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor

✍ H.A. Burris; G. Hudes; S. Jones; J. Cheng; D. Spigel; M. Mariani; H. Macdonald; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

496 A phase I dose-escalation study of B

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

✍ M. Scheulen; K. Mross; H. Richly; B. Nokay; A. Frost; D. Scharr; K.H. Lee; O. Sa 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 64 KB

403 Phase I study on RGB-286638, a novel

403 Phase I study on RGB-286638, a novel, multi-targeted protein kinase inhibitor, administered as a 1-hour infusion on five consecutive days every 4 weeks in patients (pts) with recurrent or refractory solid tumors

✍ M. de Jonge; R. Mathijssen; W. Loos; H. Loferer; S. Sperka; T. Meyer; E. Wiemer; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB